Kamran Alam
2020 - Taysha Gene Therapies
In 2020, Kamran Alam earned a total compensation of $5.5M as Chief Financial Officer at Taysha Gene Therapies.
Compensation breakdown
| Non-Equity Incentive Plan | $85,217 |
|---|---|
| Salary | $142,088 |
| Stock Awards | $4,933,703 |
| Other | $330,153 |
| Total | $5,491,161 |
Alam received $4.9M in stock awards, accounting for 90% of the total pay in 2020.
Alam also received $85.2K in non-equity incentive plan, $142.1K in salary and $330.2K in other compensation.
Rankings
In 2020, Kamran Alam's compensation ranked 1,962nd out of 13,090 executives tracked by ExecPay. In other words, Alam earned more than 85.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,962 out of 13,090 | 85th |
Division Manufacturing | 761 out of 5,621 | 87th |
Major group Chemicals And Allied Products | 271 out of 2,254 | 88th |
Industry group Drugs | 228 out of 1,954 | 88th |
Industry Biological Products, Except Diagnostic Substances | 67 out of 411 | 84th |
Source: SEC filing on April 28, 2022.
Alam's colleagues
We found two more compensation records of executives who worked with Kamran Alam at Taysha Gene Therapies in 2020.
News
Taysha Gene Therapies CEO Sean Nolan's 2023 pay slips 20% to $1.5M
April 18, 2024
Taysha Gene Therapies CEO RA Session's 2022 pay falls 57% to $2M
May 8, 2023
Taysha Gene Therapies CEO RA Session's 2021 pay slips 3% to $4.6M
April 28, 2022
Inotek Pharmaceuticals CEO Gaurav Shah's 2019 pay falls 39% to $3.9M
April 24, 2020
Aquinox Pharmaceuticals CEO Jonathan Drachman receives $3.8M in 2019
March 24, 2020
Aquinox Pharmaceuticals CEO David Main's 2018 pay jumps 39% to $4.2M
October 2, 2019